A PHASE IV NON-INTERVENTIONAL STUDY. ADVERSE EVENTS (AES)/SUSPECTED ADVERSE DRUG REACTIONS (SADRS) ON THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN ADULT PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION WITH ONE OR MORE RISK FACTORS AS PRIOR STOKE OR TRANSIENT ISCHAEMIC ATTACK; AGE >75; HYPERTENSION; DIABETES MELLITUS; SYMPTOMATIC HEART FAILURE (NYHA CLASS >II) AND PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN ADULT PATIENTS WHO HAVE UNDERGONE ELECTIVE HIP OR KNEE REPLACEMENT SURGERY UNDER TREATMENT WITH ELICUIS (REGISTERED) (APIXABAN)
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions
- Sponsors Pfizer
- 14 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Mar 2021 Planned End Date changed from 29 Dec 2023 to 1 Mar 2024.
- 29 Mar 2021 Planned initiation date changed from 17 Aug 2020 to 1 Sep 2021.